ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Treatment of Late Antibody-Mediated Rejection in Primary Renal Transplant Recipients – A Single Center Experience

R. Prashar, A. Patel, K. Venkat.

Division of Nephrology and Transplant Institute, Henry Ford Hospital, Detroit, MI.

Meeting: 2015 American Transplant Congress

Abstract number: A125

Keywords: Antibodies, Graft survival, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session A: Kidney Antibody Mediated Rejection

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Background: Successful reversal of early post-transplant antibody mediated rejection (AMR) is well documented, but data on the results of treatment of late AMR are lacking. We present a single center experience of 13 consecutive patients treated for late AMR.

Methods: All recipients of a primary kidney-only transplant between 2008-2012 at our institution were retrospectively reviewed. Late AMR was defined as rejection > 6 months posttransplant. Diffuse/circumferential C4d positivity and peritubular capillaritis along with presence of de-novo anti-HLA donor-specific antibodies (DSA) were used to diagnose AMR in for-cause biopsies. Median follow up post biopsy was 290 days (63-2048 days).

Results: Out of 517 primary renal transplants done during this period, 13 patients had late AMR occurring 7-24 months post-transplant: 10/13(77%) had mixed AMR and cell-mediated rejection; transplant glomerulopathy and peritubular capillary basement membrane multilayering were seen in 3 patients (23%); 61%(8/13) patients had moderate to severe IF-TA. Proteinuria at biopsy varied between none to 2.8 g/g of creatinine. Noncompliance contributed to rejection in 5/13(38%) patients. Treatment: 6/13(46%) patients received plasmapheresis + intravenous immune globulin (IVIg) + thymoglobulinR + IV steroids; 5/13 patients received rituximab + the above combination. One patient with pure AMR was treated with plasmapheresis + IVIg alone; 1 patient received only steroids(had severe IFTA). While initial improvement was observed in 9/13(69%) patients, with a decline in SCr from 7.9(+/- 6.2) to 3.1(+/- 1.0) mg/dl and decline in DSA strength, sustained improvement was seen only in 4/13(31%) patients over 250-2048 days. No improvement was seen in patients who presented with a SCr >6.1 mg/dl, except in 1 patient. Overall incidence of graft loss was 46%(6/13) within 8 months of treatment of late AMR; 31%(4/13) of patients had serious infections (blastomycosis, pyelonephritis, cytomegalovirus syndrome and bacteremia) after treatment for AMR and 1 patient (8%) died from severe sepsis.

Conclusions: Our data suggest poor response to therapy in patients treated for AMR >6 months post-transplant, with unacceptably high risk of infectious complications. The risk of therapy of late AMR should be weighed against benefits, especially in patients with advanced renal failure and/or histological findings suggesting chronicity.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Prashar R, Patel A, Venkat K. Outcomes of Treatment of Late Antibody-Mediated Rejection in Primary Renal Transplant Recipients – A Single Center Experience [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-treatment-of-late-antibody-mediated-rejection-in-primary-renal-transplant-recipients-a-single-center-experience/. Accessed May 20, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences